The company completed a clinical trial at nine centers across the U.S., Europe and Asia before it received FDA approval.

New research shows that inhibiting overactive LRRK2 enzymes could stabilize Parkinson's disease progression, with Stanford ...

Dr. Simrit Parmar, a Northwestern University-trained oncologist and research scientist, launched Cellenkos Inc., in 2016 to ...

A team of neuroscientists in Australia has found that restoring copper levels in the brain dramatically reduced Parkinson-like damage in mice. The approach restored a protein’s function, and the same ...

The findings of two recent studies give hope that the disease could one day be reversed in humans—but experts warn that this ...

A new weekly injectable drug could transform the lives of more than eight million people living with Parkinson's disease, ...

Ambroxol, long used for coughs in Europe, stabilized symptoms and brain-damage markers in Parkinson’s dementia patients over ...

Parkinson's disease is a neurogenerative disease that affects more than 1 million people in the U.S. While some cases are ...

An active ingredient in cough medicines since 1979 has shown promise as a treatment for neuropsychiatric symptoms in ...

The drug is Ambroxol. It’s been used for decades to treat respiratory ailments by thinning mucus and easing coughs. But now, ...

Groundbreaking research by Sydney University found a new brain protein involved in Parkinson’s disease and a way to modify it ...

Scientists have discovered how a key protein helps maintain strong connections between brain cells that are crucial for ...